Perceptions of the public healthcare system from private-care patients with irritable bowel syndrome with constipation in Spain

Mira, José Joaquín; Lacima, Gloria; Gil, Xavier Cortés

doi:10.17235/reed.2018.5526/2018

Cited by 7 publications

(5 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, such medications only relief related symptoms rather than disease modi cation, and the recurrence rates are high [8]. Many patients are reluctant to continued use medication due to few symptom improvements [9] and adverse effects, such as cardiovascular disorders and ischemic colitis [10]. Therefore, there is urgent to search for the therapies that effectively treat and manage this condition [11].…”

Section: Introductionmentioning

confidence: 99%

Mild moxibustion for Irritable Bowel Syndrome with Diarrhea (IBS-D): A randomized controlled trial

Wang

Shi

et al. 2022

Journal of Ethnopharmacology

View full text Add to dashboard Cite

To evaluate the effects of mild moxibustion (MM) for the treatment of irritable bowel syndrome with diarrhea (IBS-D) through comparisons with those of placebo moxibustion. Patients and Methods:This was a single-site, randomized controlled trial was conducted at Shanghai Research Institute of Acupuncture and Meridian in China and enrolled 76 participants who met the Rome IV diagnostic criteria for IBS-D between May 2017 and December 2019. 76 participants were randomized to either mild moxibustion (MM) or placebo moxibustion group (PM) in a 1:1 ratio. 18 sessions of MM or PM were implemented over the course of 6 weeks (3 times per week). The primary outcome was adequate relief after 6 weeks of treatment. ResultsOf 76 patients with IBS-D who were randomized (38 in the MM group and 38 in the PM group) were included in the intention-to-treat (ITT) analysis set. After treatment at week 6, the response rate was signi cantly higher in the MM group than the PM group (81.58% vs. 36.84%,) with an estimated difference of 44.74 (95% CI, 23.46 to 66.02, P < 0.001). No participant reported severe adverse effects. ConclusionThe ndings suggest that mild moxibustion may be more effective than placebo moxibustion for the treatment of IBS-D, with effects lasting up to 12 weeks.

show abstract

Section: Introductionmentioning

confidence: 99%

Mild moxibustion for Irritable Bowel Syndrome with Diarrhea (IBS-D): A randomized controlled trial

Wang

Shi

et al. 2022

Journal of Ethnopharmacology

View full text Add to dashboard Cite

show abstract

“…7 A large proportion of patients (60.1%) reportedly discontinued medication because of dissatisfaction attributed to few symptom improvements. 8 Moreover, the side effects, including headache, dizziness, dry mouth, and insomnia, cannot be neglected. In particular, severe adverse events (AEs) such as cardiovascular disorders and ischemic colitis may occur with long-term use.…”

mentioning

confidence: 99%

Effect of Acupuncture in Patients With Irritable Bowel Syndrome: A Randomized Controlled Trial

Pei

Geng

Guo

et al. 2020

Mayo Clinic Proceedings

View full text Add to dashboard Cite

Objective: To evaluate the effect and safety of acupuncture for the treatment of irritable bowel syndrome (IBS) through comparisons with those of polyethylene glycol (PEG) 4000 and pinaverium bromide. Patients and Methods: This multicenter randomized controlled trial was conducted at 7 hospitals in China and enrolled participants who met the Rome III diagnostic criteria for IBS between May 3, 2015, and June 29, 2018. Participants were first stratified into constipation-predominant or diarrheapredominant IBS group. Participants in each group were randomly assigned in a 2:1 ratio to receive acupuncture (18 sessions) or PEG 4000 (20 g/d, for IBS-C)/pinaverium bromide (150 mg/d, for IBS-D) over a 6-week period, followed by a 12-week follow-up. The primary outcome was change in total IBS-Symptom Severity Score from baseline to week 6. Results: Of 531 patients with IBS who were randomized, 519 (344 in the acupuncture group and 175 in the PEG 4000/ pinaverium bromide group) were included in the full analysis set. From baseline to 6 weeks, the total IBS-Symptom Severity Score decreased by 123.51 (95% CI, 116.61 to 130.42) in the acupuncture group and 94.73 (95% CI, 85.03 to 104.43) in the PEG 4000/pinaverium bromide group. The between-group difference was 28.78 (95% CI, 16.84 to 40.72; P<.001). No participant experienced severe adverse effects. Conclusion: Acupuncture may be more effective than PEG 4000 or pinaverium bromide for the treatment of IBS, with effects lasting up to 12 weeks.

show abstract

“…At present, individualized symptomatic treatments, including antidiarrheal, improving intestinal motility, antidepressant, supplemented by psychotherapy and diet conditioning can only temporarily relieve individual symptoms, and a large number of patients reportedly discontinued the medications because of dissatisfaction. [8,9] Moreover, many side effects, including headache, dizziness, dry mouth, and insomnia, cardiovascular disorders, and ischemic colitis have been reported after longterm use of those medications. [10] In recent years, complementary and alternative medicine (CAM) has become widely accepted in IBS patients, and more than half of D-IBS patients have received CAM.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of Qinghua Zhixie Decoction against diarrhea-predominate irritable bowel syndrome

Zhao

Zhang

et al. 2022

Medicine

View full text Add to dashboard Cite

Background: Diarrhea-predominant irritable bowel syndrome (D-IBS) is the main subtypes of irritable bowel syndrome (IBS). In recent years, more than half of IBS patients have received complementary and alternative medicine. Traditional Chinese herbal formula is widely used in Asia, and clinical studies have also found that Chinese herbal formula could significantly improve abdominal pain and diarrhea. We plan to carry out a randomized, controlled, double blind, clinical studies to observe the clinical efficacy of Qinghua Zhixie decoction in the treatment of D-IBS. Methods: Four hundred sixty-four participants will be randomly assigned to the treatment group and control group. Patients in both groups would take medications and stimulations simultaneously. The outcomes of IBS symptom severity score, quality of life, psychological states, and recurrence rate will be recorded. Statistics will be analyzed with the SPSS 22.0. Conclusions: The findings of the study will identify the safety and efficacy of Qinghua Zhixie decoction in the treatment of D-IBS. Trial registration: OSF Registration number: DOI 10.17605/OSF.IO/C8MHW.

show abstract

Perceptions of the public healthcare system from private-care patients with irritable bowel syndrome with constipation in Spain

Cited by 7 publications

References 25 publications

Mild moxibustion for Irritable Bowel Syndrome with Diarrhea (IBS-D): A randomized controlled trial

Mild moxibustion for Irritable Bowel Syndrome with Diarrhea (IBS-D): A randomized controlled trial

Effect of Acupuncture in Patients With Irritable Bowel Syndrome: A Randomized Controlled Trial

Efficacy and safety of Qinghua Zhixie Decoction against diarrhea-predominate irritable bowel syndrome

Contact Info

Product

Resources

About